These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 11885733)

  • 21. Prevention and control of meningococcal disease. Recommendations of the Advisory Committee on Immunization Practices (ACIP).
    Bilukha OO; Rosenstein N;
    MMWR Recomm Rep; 2005 May; 54(RR-7):1-21. PubMed ID: 15917737
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The costs associated with the public health management of a cluster of meningococcal infection in England.
    Letouze D; Yao G; Clarke SC
    Vaccine; 2014 Sep; 32(43):5549-51. PubMed ID: 25173479
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies.
    Ruedin HJ; Ess S; Zimmermann HP; Szucs T
    Vaccine; 2003 Oct; 21(27-30):4145-52. PubMed ID: 14505894
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cost-effectiveness analysis of a multicomponent meningococcal serogroup B vaccine in hypothetic epidemic situation in a middle-income country.
    Izquierdo G; Torres JP; Santolaya ME; Valenzuela MT; Vega J; Chomali M
    Hum Vaccin Immunother; 2015; 11(4):875-83. PubMed ID: 25714390
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Control of invasive meningococcal disease: is it achievable?
    Marshall H; Wang B; Wesselingh S; Snape M; Pollard AJ
    Int J Evid Based Healthc; 2016 Mar; 14(1):3-14. PubMed ID: 26126001
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cost-benefit model comparing two alternative immunisation programmes against serogroup C meningococcal disease: for Quebec residents aged 2 months to 20 years.
    Rancourt C; Grégoire JP; Simons W; Dostie A
    Pharmacoeconomics; 2003; 21(6):429-42. PubMed ID: 12678569
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Adolescent, parent and societal preferences and willingness to pay for meningococcal B vaccine: A Discrete Choice Experiment.
    Marshall HS; Chen G; Clarke M; Ratcliffe J
    Vaccine; 2016 Jan; 34(5):671-677. PubMed ID: 26740249
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Cost-effectiveness of expanding childhood routine immunization against Neisseria meningitidis serogroups C, W and Y with a quadrivalent conjugate vaccine in the African meningitis belt.
    Kuznik A; Iliyasu G; Lamorde M; Mahmud M; Musa BM; Nashabaru I; Obaro S; Mohammed I; Habib AG
    PLoS One; 2017; 12(11):e0188595. PubMed ID: 29190699
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cost-effectiveness Comparison of Monovalent C Versus Quadrivalent ACWY Meningococcal Conjugate Vaccination in Canada.
    De Wals P; Zhou Z
    Pediatr Infect Dis J; 2017 Jul; 36(7):e203-e207. PubMed ID: 28027288
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Economic analysis of the 1992-1993 mass immunization campaign against serogroup C meningococcal disease in Quebec.
    De Wals P; Erickson L
    Vaccine; 2002 Jun; 20(21-22):2840-4. PubMed ID: 12102036
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of meningococcal C conjugate vaccination programs with and without catch-up campaigns in adolescents: Lessons learned from Bahia, Brazil.
    Evellyn do Macedo L; Ferreira VM; Feitosa CA; Nunes AMPB; Campos LC; Sáfadi MAP
    Hum Vaccin Immunother; 2018 May; 14(5):1131-1137. PubMed ID: 29236585
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Meningococcal C vaccines: the Canadian experience.
    De Wals P
    Pediatr Infect Dis J; 2004 Dec; 23(12 Suppl):S280-4. PubMed ID: 15597070
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Estimating the burden of serogroup C meningococcal disease in England and Wales.
    Davison KL; Ramsay ME; Crowcroft NS; Lieftucht A; Kaczmarski EB; Trotter CL; Gungabissoon U; Begg NT
    Commun Dis Public Health; 2002 Sep; 5(3):213-9. PubMed ID: 12434691
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The role of economic evaluation in vaccine decision making: focus on meningococcal group C conjugate vaccine.
    Welte R; Trotter CL; Edmunds WJ; Postma MJ; Beutels P
    Pharmacoeconomics; 2005; 23(9):855-74. PubMed ID: 16153131
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Cost-effectiveness analysis of a universal infant immunization program with meningococcal C conjugate vaccine in Brazil.
    de Soarez PC; Sartori AM; de Andrade Lagoa Nóbrega L; Itria A; Novaes HM
    Value Health; 2011 Dec; 14(8):1019-27. PubMed ID: 22152170
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immunisation against meningococcus B.
    Eskola J
    Lancet; 2013 Sep; 382(9897):1019. PubMed ID: 24054532
    [No Abstract]   [Full Text] [Related]  

  • 37. Modelling the cost-effectiveness of catch-up 'MenB' (Bexsero) vaccination in England.
    Christensen H; Trotter CL
    Vaccine; 2017 Jan; 35(2):208-211. PubMed ID: 27923519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact on disease incidence of a routine universal and catch-up vaccination strategy against Neisseria meningitidis C in Tuscany, Italy.
    Bechini A; Levi M; Boccalini S; Tiscione E; Balocchini E; Canessa C; Azzari C; Bonanni P
    Vaccine; 2012 Oct; 30(45):6396-401. PubMed ID: 22921931
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Should college students be vaccinated against meningococcal disease? A cost-benefit analysis.
    Jackson LA; Schuchat A; Gorsky RD; Wenger JD
    Am J Public Health; 1995 Jun; 85(6):843-5. PubMed ID: 7762722
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Surveillance for meningococcal disease and strategies for use of conjugate meningococcal vaccines in the United States.
    Lingappa JR; Rosenstein N; Zell ER; Shutt KA; Schuchat A; Perkins BA;
    Vaccine; 2001 Aug; 19(31):4566-75. PubMed ID: 11483285
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.